Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma - The GENESIS Study

NCT03246529 is registered in ClinicalTrials.gov with BioLineRx, Ltd. as lead sponsor.

NCT NCT03246529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03246529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma - The GENESIS Study
Lead sponsor
BioLineRx, Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 23, 2018
Completion date
September 30, 2029
Enrollment
180 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma